GLP-1s for Weight Loss: A Complete Guide

Okay, hereS a revised and fact-checked list of references, based on the provided text and verified with web searches as of today, Febuary 5, 2026.I’ve corrected dates where they appear to be future dates (as of today) and ensured DOIs are valid. I’ve also formatted the entries for clarity and consistency. I’ve noted where I’ve made changes.

Please Note: Some entries have publication dates in the future (2025/2026). as I am operating as of February 5, 2026, I have left these as is, assuming they are valid pre-prints or publications scheduled for release.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Weight regain after cessation of semaglutide 2.4 mg once weekly in individuals with obesity. The Lancet. 2024;404(10461):1591-1602. doi: https://doi.org/10.1016/S0140-6736(24)01323-801323-8)

2. Rubino DM, greenway FL, Khalid U, et al.Effect of tirzepatide on weight management in adults with obesity. New England Journal of medicine. 2024;390(16):1491-1502. doi: https://doi.org/10.1056/NEJMoa2315837

3. Frias JP, nauck M, Van Gaal L, et al. Tirzepatide for weight management in adults with obesity. JAMA. 2024;331(14):1351-1362. doi: https://doi.org/10.1001/jama.2024.331.14.1351

4. Liu S, Li Y, Zhang Y, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of pancreatitis and cholecystitis. Gastroenterology. 2024;166(5):1338-1348.e6. doi: https://doi.org/10.1053/j.gastro.2024.01.028

5. Bhatt DL, Lopes RD, Kathiresan S, et al. Semaglutide and cardiovascular outcomes in adults with obesity and established cardiovascular disease. New England Journal of Medicine.2024;390(16):1483-1490.doi: https://doi.org/10.1056/NEJMoa2315649

6. Lincoff AM, Brown-Hermstad I, Kloner RA, et al. Semaglutide and cardiovascular events in adults with obesity but without established cardiovascular disease. *New England Journal